Premium
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft‐versus‐host disease
Author(s) -
Hurabielle C.,
Sicre de Fontbrune F.,
MoinsTeisserenc H.,
Robin M.,
Jachiet M.,
Coman T.,
Dhedin N.,
Cassius C.,
Chasset F.,
Masson A.,
Michonneau D.,
Bagot M.,
Bergeron A.,
Socié G.,
Peffault de Latour R.,
Bouaziz J.D.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15593
Subject(s) - ruxolitinib , graft versus host disease , medicine , refractory (planetary science) , host (biology) , immunology , disease , biology , bone marrow , myelofibrosis , ecology , astrobiology